Received Mar 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | — |
HCP is a clinical trial professional requesting information on PNEUMOVAX 23. HCP reports they have a patient who is over the age of 50 and received 1 dose of PNEUMOVAX 23 about 4 years ago in 2022. The clinical trial requires that all participants be; This Spontaneous report was received from a health professional who was a clinical trial professional and referred to a patient who was over the age of 50 of unknown gender. No information was provided regarding the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant medication. In 2022 (also reported as ''about 4 years ago''), the patient received 1 dose of Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported) (Product use issue). The clinical trial required that all participants be fully vaccinated for pneumococcal. The health care professional was inquiring whether additional pneumococcal vaccination was needed for patient. The health care professional did not report any symptoms and did not have any medical history available; she was unsure if patient had ever missed any pneumococcal vaccinations. Lot # is being requested and will be submitted if received.